Form 4: Astria Therapeutics Director Cashes Out Options Post-Merger

Astria Therapeutics Director Anthony Gregg Lapointe reported the cancellation of in-the-money stock options for cash following the company's merger with BioCryst Pharmaceuticals.

Summary

• Anthony Gregg Lapointe, a Director of Astria Therapeutics, Inc. (ATXS), reported changes in his beneficial ownership of securities.
• The changes occurred on January 23, 2026, following the merger of Astria Therapeutics, Inc. with Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst Pharmaceuticals, Inc.
• Astria Therapeutics, Inc. survived the merger and became a wholly-owned subsidiary of BioCryst Pharmaceuticals, Inc.
• Stock options with an exercise price less than $13.00 ('In-the-Money Options') became fully vested, exercisable, and were canceled in exchange for a cash payment.
• The cash payment for each In-the-Money Option was calculated as the total number of shares subject to the option multiplied by the excess of $13.00 over the option's exercise price.
• Stock options with an exercise price equal to or greater than $13.00 ('Out-of-the-Money Options') were canceled for no consideration and are not reported.
• Mr. Lapointe's reported In-the-Money options included: 16,666 shares at $12.24, 8,333 shares at $3.00, 14,100 shares at $11.35, 14,100 shares at $9.18, and 26,550 shares at $5.79.
• These numbers reflect adjustments for a 1-for-6 reverse stock split effected by the Issuer on August 19, 2021.
• The total cash received by Mr. Lapointe for the cancellation of his In-the-Money options is approximately $364,548.66.

Sentiment

Score: 7

Explanation: The sentiment is positive for the reporting person, as they successfully monetized their in-the-money stock options for a significant cash sum following the merger. For the company, the merger's completion is a neutral event in this context, as it was a planned strategic move.

Positives

• Director Anthony Gregg Lapointe received a cash payout of approximately $364,548.66 for his in-the-money stock options.
• The merger of Astria Therapeutics, Inc. with BioCryst Pharmaceuticals, Inc. was successfully completed.

Negatives

• Astria Therapeutics, Inc. is no longer an independent publicly traded company, becoming a wholly-owned subsidiary of BioCryst Pharmaceuticals, Inc.
• Out-of-the-money stock options held by the reporting person were canceled for no consideration.

Future Outlook

The filing reports a completed merger and the subsequent treatment of stock options; it does not provide any forward-looking statements or guidance regarding the future operations or financial performance of the combined entity.

Industry Context

This filing reflects a consolidation event within the biotechnology and pharmaceutical industry, where a smaller entity (Astria Therapeutics) is acquired by a larger one (BioCryst Pharmaceuticals). Such mergers are common for strategic reasons, including pipeline expansion, market share growth, or operational synergies.

Stakeholder Impact

• Shareholders of Astria Therapeutics, Inc. would have received consideration for their shares as part of the merger, though the specific terms are not detailed in this Form 4.
• Employees of Astria Therapeutics, Inc. are now part of BioCryst Pharmaceuticals, Inc., potentially impacting their roles and benefits.
• The reporting person, a director, received a cash payout for his vested options, indicating a positive financial outcome for him from the merger.

Key Dates

Keywords

Astria Therapeutics, ATXS, BioCryst Pharmaceuticals, Merger, Stock Options, Form 4, Insider Transaction, Beneficial Ownership, Corporate Acquisition